ColumbiaMagazine.com
Printed from:

Welcome to Columbia Magazine  
 



































 
AG returns nearly $8 million to General Fund

Office secures more than $1 million for General Fund this week, which goes projected shortfall of $113 in state budget
Click on headline for complete story

By Terry Sebastian
News from the Kentucky Attorney General's Office

FRANKFORT, KY. (30 Jun 2017) - As the current fiscal year ends, Attorney General Andy Beshear today announced that his office has returned nearly $8 million to the state's General Fund from a variety of civil settlements over the last 12 months.



Included in that amount is $574,000 Beshear returned today to the state's General Fund from a settlement with a Johnson & Johnson subsidiary. Combined with Beshear's Bryant Heating and Cooling Co. Inc. settlement, the AG's office has secured more than $1 million for the state this week.

The Johnson & Johnson settlement resolves allegations that McNeil Consumer Healthcare Division, which is now a division of Johnson & Johnson Consumer Inc., promoted over-the-counter drugs as complying with federally mandated manufacturing standards even though the U.S. Food and Drug Administration found that some of its manufacturing facilities were not in compliance with federal standards between 2009 and 2011.

The drugs include Tylenol, Motrin, Benadryl, St. Joseph Aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec and Zyrtec Eye Drops - all manufactured and distributed by McNeil Consumer Healthcare Division.

"At a time when the state is facing a projected current fiscal year budget shortfall of $113 million, I'm proud my office is doing its part to secure millions of dollars for our state coffers," Beshear said.

These civil settlements include Mortgage Electronic Registration Systems Inc. (MERS), Volkswagen, Hyundai-Kia, Bristol-Myers Squibb, Western Union, Target, Bryant Heating and Cooling Co. Inc. and Johnson & Johnson Consumer Inc.

Beshear is currently in civil litigation against Johnson & Johnson and its medical device unit, Ethicon, for its deceptive marketing of surgical transvaginal mesh.


This story was posted on 2017-07-01 09:14:23
Printable: this page is now automatically formatted for printing.
Have comments or corrections for this story? Use our contact form and let us know.



 

































 
 
Quick Links to Popular Features


Looking for a story or picture?
Try our Photo Archive or our Stories Archive for all the information that's appeared on ColumbiaMagazine.com.

 

Contact us: Columbia Magazine and columbiamagazine.com are published by Linda Waggener and Pen Waggener, PO Box 906, Columbia, KY 42728.
Phone: 270.403.0017


Please use our contact page, or send questions about technical issues with this site to webmaster@columbiamagazine.com. All logos and trademarks used on this site are property of their respective owners. All comments remain the property and responsibility of their posters, all articles and photos remain the property of their creators, and all the rest is copyright 1995-Present by Columbia Magazine. Privacy policy: use of this site requires no sharing of information. Voluntarily shared information may be published and made available to the public on this site and/or stored electronically. Anonymous submissions will be subject to additional verification. Cookies are not required to use our site. However, if you have cookies enabled in your web browser, some of our advertisers may use cookies for interest-based advertising across multiple domains. For more information about third-party advertising, visit the NAI web privacy site.